Mangan C, Jeglum K A, Sedlacek T V, Giuntoli R L, Wheeler J E, Rubin E, Mikuta J J
Cancer. 1977 Dec;40(6):2933-40. doi: 10.1002/1097-0142(197712)40:6<2933::aid-cncr2820400627>3.0.co;2-j.
Thirteen patients with a variety of advanced gynecologic malignancies were administered BCG via the dorsal lymphatics of the lower extremity in addition to standard accepted forms of therapy. Prolonged febrile courses, lymphangitis and suppurative adenitis were observed along the lymphatic pathway of the injected lower limbs. There was no correlation between reaction to a standard anergy panel and survival. There was also no correlation between reaction to a standard anergy panel and the inflammatory response to intralymphatic BCG (ILP-BCG). There was, however, a positive correlation between the inflammatory response to ILP-BCG and survival. Intralymphatic administration of immunostimulants may conceivably be of value as ancillary therapy for use in gynecologic malignancy. However, complications of this approach to immunotherapy are significant and the method should not be used until complications are decreased.
13例患有各种晚期妇科恶性肿瘤的患者，除了接受标准的公认治疗形式外，还通过下肢背侧淋巴管给予卡介苗。在注射侧下肢的淋巴途径中观察到持续的发热过程、淋巴管炎和化脓性腺炎。对标准无反应性检测的反应与生存率之间没有相关性。对标准无反应性检测的反应与对淋巴内卡介苗（ILP-BCG）的炎症反应之间也没有相关性。然而，对ILP-BCG的炎症反应与生存率之间存在正相关。淋巴内给予免疫刺激剂作为妇科恶性肿瘤的辅助治疗可能具有一定价值。然而，这种免疫治疗方法的并发症很严重，在并发症减少之前不应使用该方法。
